Last reviewed · How we verify

Inborn error of bile acid metabolism — Treatment Landscape & Competitive Intelligence

Inborn error of bile acid metabolism (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Inborn error of bile acid metabolism, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Cholbam CHOLIC ACID Mirum Bile Acid [EPC] G-protein coupled bile acid receptor 1 2015-01-01
Cholbam Cholbam Mirum Pharmaceuticals, Inc. G-protein coupled bile acid receptor 1, Bile acid receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Mirum · 1 drug in Inborn error of bile acid metabolism
  2. Mirum Pharmaceuticals, Inc. · 1 drug in Inborn error of bile acid metabolism

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Inborn error of bile acid metabolism:

Cite this brief

Drug Landscape (2026). Inborn error of bile acid metabolism — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/inborn-error-of-bile-acid-metabolism. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing